StemRIM Company Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases.

The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy.

Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy.

StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

StemRIM

Country	Japan
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	44
CEO	Masatsune Okajima

Contact Details

Address: Saito Bio-Incubator Ibaraki, 567-0085 Japan
Phone	81 72 648 7152
Website	stemrim.com

Stock Details

Ticker Symbol	4599
Exchange	Tokyo Stock Exchange
Fiscal Year	August - July
Reporting Currency	JPY
ISIN Number	JP3399690001
SIC Code	2836

Key Executives

Name	Position
Masatsune Okajima	Chief Executive Officer